NCT02672293View on ClinicalTrials.gov

Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate

NACompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 18, 2018

Study Completion Date

April 18, 2018

Conditions
Chronic Kidney Disease
Interventions
DRUG

Phoslax

Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).

Trial Locations (1)

K7L 3N6

Kingston General Hospital, Kingston

All Listed Sponsors
lead

Dr. Rachel Holden

OTHER

NCT02672293 - Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate | Biotech Hunter | Biotech Hunter